|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Allis CD, Berger SL, Cote J, et al: New
nomenclature for chromatin-modifying enzymes. Cell. 131:633–636.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cantone I and Fisher AG: Epigenetic
programming and reprogramming during development. Nat Struct Mol
Biol. 20:282–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Albig AR, Neil JR and Schiemann WP:
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res.
66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yue W, Dacic S, Sun Q, et al: Frequent
inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter
hypermethylation. Clin Cancer Res. 13:4336–4344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nomoto S, Kanda M, Okamura Y, et al:
Epidermal growth factor-containing fibulin-like extracellular
matrix protein 1, EFEMP1, a novel tumor suppressor gene detected in
hepatocellular carcinoma using double combination array analysis.
Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar
|
|
7
|
Kim YJ, Yoon HY, Kim SK, et al: EFEMP1 as
a novel DNA methylation marker for prostate cancer: array-based DNA
methylation and expression profiling. Clin Cancer Res.
17:4523–4530. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadr-Nabavi A, Ramser J, Volkmann J, et
al: Decreased expression of angiogenesis antagonist EFEMP1 in
sporadic breast cancer is caused by aberrant promoter methylation
and points to an impact of EFEMP1 as molecular biomarker. Int J
Cancer. 124:1727–1735. 2009. View Article : Google Scholar
|
|
9
|
Hwang CF, Chien CY, Huang SC, et al:
Fibulin-3 is associated with tumour progression and a poor
prognosis in nasopharyngeal carcinomas and inhibits cell migration
and invasion via suppressed AKT activity. J Pathol. 222:367–379.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
En-lin S, Sheng-guo C and Hua-qiao W: The
expression of EFEMP1 in cervical carcinoma and its relationship
with prognosis. Gynecol Oncol. 117:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davidson B, Stavnes HT, Holth A, Chen X,
Yang Y, et al: Gene expression signatures differentiate
ovarian/peritoneal serous carcinoma from breast carcinoma in
effusions. J Cell Mol Med. 15:535–544. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seeliger H, Camaj P, Ischenko I, et al:
EFEMP1 expression promotes in vivo tumor growth in human pancreatic
adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fahrner JA, Eguchi S, Herman JG and Baylin
SB: Dependence of histone modifications and gene expression on DNA
hypermethylation in cancer. Cancer Res. 62:7213–7218.
2002.PubMed/NCBI
|
|
14
|
Cameron EE, Bachman KE, Myöhänen S, Herman
JG and Baylin SB: Synergy of demethylation and histone deacetylase
inhibition in the re-expression of genes silenced in cancer. Nat
Genet. 21:103–107. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuo MH and Allis CD: In vivo cross-linking
and immunoprecipitation for studying dynamic Protein:DNA
associations in a chromatin environment. Methods. 19:425–433. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Zhang YW and Chen LB: Aberrant
promoter methylation of FBLN-3 gene and clinicopathological
significance in non-small cell lung carcinoma. Lung Cancer.
69:239–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
|
|
18
|
Meng CF, Zhu XJ, Peng G and Dai DQ: Role
of histone modifications and DNA methylation in the regulation of
O6-methylguanine-DNA methyltransferase gene expression
in human stomach cancer cells. Cancer Invest. 28:331–339. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng CF, Zhu XJ, Peng G and Dai DQ:
Promoter histone H3 lysine 9 di-methylation is associated with DNA
methylation and aberrant expression of p16 in gastric cancer cells.
Oncol Rep. 22:1221–1227. 2009.PubMed/NCBI
|
|
20
|
Chang X, Zhang S, Ma J, et al: Association
of NDRG1 gene promoter methylation with reduced NDRG1 expression in
gastric cancer cells and tissue specimens. Cell Biochem Biophys.
66:93–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grewal SI and Moazed D: Heterochromatin
and epigenetic control of gene expression. Science. 301:798–802.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peters AH, Mermoud JE, O’Carroll D, et al:
Histone H3 lysine 9 methylation is an epigenetic imprint of
facultative heterochromatin. Nat Genet. 30:77–80. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y and Marmorstein LY: Focus on
molecules: fibulin-3 (EFEMP1). Exp Eye Res. 90:374–375. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu Y, Pioli PD, Siegel E, et al: EFEMP1
suppresses malignant glioma growth and exerts its action within the
tumor extracellular compartment. Mol Cancer. 10:1232011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim EJ, Lee SY, Woo MK, et al: Fibulin-3
promoter methylation alters the invasive behavior of non-small cell
lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol.
40:402–408. 2012.PubMed/NCBI
|
|
26
|
Tong JD, Jiao NL, Wang YX, Zhang YW and
Han F: Downregulation of fibulin-3 gene by promoter methylation in
colorectal cancer predicts adverse prognosis. Neoplasma.
58:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang T, Qiu H, Bao W, et al: Epigenetic
inactivation of EFEMP1 is associated with tumor suppressive
function in endometrial carcinoma. PLoS One. 8:e674582013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: how the genome integrates intrinsic
and environmental signals. Nat Genet. 33(Suppl): 245–254. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nawrocki ST, Carew JS, Douglas L, et al:
Histone deacetylase inhibitors enhance lexatumumab-induced
apoptosis via a p21Cip1-dependent decrease in survivin levels.
Cancer Res. 67:6987–6994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang X, Li Z, Ma J, et al: DNA
methylation of NDRG2 in gastric cancer and its clinical
significance. Dig Dis Sci. 58:715–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhi Y, Chen J, Zhang S, et al:
Down-regulation of CXCL12 by DNA hypermethylation and its
involvement in gastric cancer metastatic progression. Dig Dis Sci.
57:650–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fuks F, Hurd PJ, Deplus R and Kouzarides
T: The DNA methyltransferases associate with HP1 and the SUV39H1
histone methyltransferase. Nucleic Acids Res. 31:2305–2312. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wozniak RJ, Klimecki WT, Lau SS, Feinstein
Y and Futscher BW: 5-Aza-2′-deoxycytidine-mediated reductions in
G9A histone methyltransferase and histone H3 K9 di-methylation
levels are linked to tumor suppressor gene reactivation. Oncogene.
26:77–90. 2007.
|
|
34
|
Lin W and Dent SY: Functions of
histone-modifying enzymes in development. Curr Opin Genet Dev.
16:137–142. 2006. View Article : Google Scholar
|
|
35
|
Martin C and Zhang Y: The diverse
functions of histone lysine methylation. Nat Rev Mol Cell Biol.
6:838–849. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu Q, Yu L, Chen R, et al:
5-aza-2′-deoxycytidine improves the sensitivity of endometrial
cancer cells to progesterone therapy. Int J Gynecol Cancer.
22:951–959. 2012.
|
